| P/E (FY) | — | Sales (TTM) | $170,000 |
| Earnings (TTM) | -$16.4M | ROE | −74.67% |
| Net Margin | −9756.47% | ROIC | −244.79% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $10.6M | Trading Days | 963 |
| 52W High | 5.07 |
| 52W Low | 1.07 |
| % Off High | −77.12% |
| YTD | −37.63% | 1Y | −55.89% |
| 3Y | −63.17% | Since incept. (ann.) | −31.49% |
Reportable 100%
| Ann. Volatility (1Y) | 119.87% | Ann. Volatility (3Y) | 89.22% |
| Sharpe (1Y) | −0.19 | Sharpe (3Y) | 0.03 |
| Max Drawdown (1Y) | −76.98% | Max Drawdown (3Y) | −76.98% |
| Beta (3Y, vs SPY) | 0.43 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LGVN | Longeveron Inc. | $10.6M | — |
| BFRG | BullFrog AI Holdings, Inc. | $10.8M | — |
| XCUR | EXICURE, INC. | $11.1M | — |
| BIVI | BIOVIE INC. | $10.0M | — |
| CALC | CalciMedica, Inc. | $11.3M | — |
| KPRX | KIORA PHARMACEUTICALS INC | $11.4M | — |
| GTBP | GT Biopharma, Inc. | $11.4M | — |
| VTGN | Vistagen Therapeutics, Inc. | $9.6M | — |
| MBRX | Moleculin Biotech, Inc. | $11.7M | — |
| PHIO | Phio Pharmaceuticals Corp. | $11.7M | — |
| COCP | Cocrystal Pharma, Inc. | $12.9M |
| TPST | Tempest Therapeutics, Inc. | $12.9M | — |
